What could go wrong?

Source: https://www.westernjournal.com/george-soros-bill-gates-just-teamed-buy-covid-company/

By Jack Davis

July 19, 2021 at 3:53pm

High-profile billionaires George Soros and Bill Gates are part of a group that is buying a company that makes rapid COVID-19 tests.

The purchase of Mologic Ltd. was announced by Open Society Foundations, which Soros founded.

A release on the foundation’s website said the purchase creates “Global Access Health (GAH), a social enterprise that will seek to expand access to affordable state-of-the-art medical technology through decentralized research, development, and manufacturing in and for the Global South.”

About $41 million will be ponied up by the buyers, which include the Soros Economic Development Fund and the Bill & Melinda Gates Foundation.

The release said that the company’s technology can be used to address tropical diseases such as dengue, bilharzia and river blindness in addition to COVID-19.

The statement said the purchase “transitions a world-class for-profit company into a social enterprise and allows it to entirely reinvest its profits in pursuing these goals. This transformation will give it the ability to address gaps in the provision of global diagnostics in low-income communities and regions that profit-focused business has failed to address.”

“The COVID-19 pandemic has painfully demonstrated the fundamental inequities in global public health, and in particular the crucial importance of access in low- and middle-income countries to low-price, high-quality life-saving diagnostic tools,” said Sean Hinton, SEDF’s CEO.

The buyout means that “a cutting edge commercial business to focus all its resources on solving one of the world’s most pressing public health issues,” he added.

The company’s tests are essentially screening tests designed to identify the presence of the disease in people who show no symptoms.

In Britain, where the tests are used, the company’s so-called lateral flow tests need to be confirmed by a second test before an official diagnosis is given, Forbes reported.

However, according to The Telegraph, the company last month said it planned to sue the British government because Britain has not permitted the test to be used as planned. The statement announcing the purchase did not provide information about the status of any suit.

Roxana Bonnell, a public health expert with Open Society Foundations, said testing needs to be ramped up in many parts of the world, such as Africa.

“As we have seen during the COVID-19 pandemic, access to testing is absolutely essential when it comes to containing the spread of contagious disease — an issue that ultimately affects us all,” she said in the release.

“Testing, or diagnostics, are vital for everyday public health needs, to enable doctors and medical professionals to provide patients with proper treatment as early as possible.”

Mologic was founded in 2003 by CEO Mark Davis and his father, Paul Davis, who serves as the company’s chief scientific officer. Paul Davis used the same technology used for COVID-19 testing to create the Clearblue home pregnancy test.

“Mologic’s transition into a social enterprise is a deliberate, logical, and natural step for a company focused on delivering affordable diagnostics and biotechnology to places that have been left underserved by the relentless pursuit of profiteering,” Mark Davis said in the statement.

“With the support of our shareholders, donors, and partners, we have come a long way; we believe we have the people and the skills required for the challenges and opportunities ahead. And we hope this unique transaction will be an example for others to follow.”

The company in question: https://mologic.co.uk/

"New York, USA, and Bedford, UK, 13 December 2021: In the light of the recent developments with the Omicron variant we have been working to verify that the accuracy of the Covios® Ag lateral flow test is unaffected by new mutations.

We have performed a small analysis on clinical samples and are delighted to report that the sensitivity remains high with samples reporting S-gene target failure (characteristic of infection with Omicron). We have also performed an in-silico analysis on the Omicron variant and the results show that there are no new mutations that affect the binding capability of our antibodies to the nucleoprotein antigen, which is the part of the virus they detect. Together these data show that Covios® performs with the same high accuracy as with the original variants."